Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evasive maneuvers by hepatitis C virus.

Brett D Lindenbach1, Charles M Rice

  • 1Center for the Study of Hepatitis C, Laboratory for Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.

Hepatology (Baltimore, Md.)
|August 27, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatitis B virus covalently closed circular DNA formation in murine hepatic cells uncovers a late entry block.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Autoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohorts.

Journal of human immunity·2026
Same author

Factor VIII originates primarily from anatomically distinct subsets of liver sinusoidal endothelial cells.

Blood advances·2026
Same author

Discovery of Novel Isofunctional SARS-CoV‑2 NSP14 RNA Cap Methyltransferase Inhibitors by Structure-Based Virtual Screening.

ACS medicinal chemistry letters·2025
Same author

Autoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohorts.

medRxiv : the preprint server for health sciences·2025
Same author

Discovery, Optimization, and Evaluation of Non-Nucleoside SARS-CoV-2 NSP14 Inhibitors.

Journal of medicinal chemistry·2025
Same journal

Decoding fibrosis: Transcriptomic and clinical insights via AI-derived collagen deposition phenotypes in MASLD.

Hepatology (Baltimore, Md.)·2026
Same journal

A randomized controlled trial of stepped treatment to reduce unhealthy alcohol use in patients with chronic liver disease.

Hepatology (Baltimore, Md.)·2026
Same journal

AASLD AST NASPGHAN Practice Guideline on pediatric liver transplantation: Candidate evaluation.

Hepatology (Baltimore, Md.)·2026
Same journal

H4K12 lactylation drives TREM2high macrophages differentiation in liver fibrosis.

Hepatology (Baltimore, Md.)·2026
Same journal

Good vibrations: Using VCTE to predict hepatic decompensation in MASLD.

Hepatology (Baltimore, Md.)·2026
Same journal

One size does not fit all: Global variability in noninvasive testing for MASLD.

Hepatology (Baltimore, Md.)·2026
See all related articles

Researchers developed a novel method using hepatitis C virus (HCV) replicons to identify resistant mutants to protease inhibitors, aiding in the development of effective HCV therapies.

Area of Science:

  • Virology
  • Drug Discovery
  • Molecular Biology

Background:

  • The hepatitis C virus (HCV) serine protease is crucial for viral replication and a key target for antiviral therapies.
  • Inhibitors targeting the HCV protease have shown efficacy in cell culture, but clinical development requires understanding resistance mechanisms.
  • Developing in vitro systems to identify and study resistant variants is essential for optimizing HCV protease inhibitors.

Discussion:

  • HCV subgenomic replicons were utilized to isolate and characterize mutants resistant to a specific protease inhibitor.
  • Selection involved culturing host cells with both the inhibitor and neomycin, leveraging the replicons' neomycin resistance transduction.
  • Selected resistant replicons demonstrated replication levels comparable to parental cells, indicating functional resistance.

Related Experiment Videos

Key Insights:

  • Amino acid substitutions within the HCV protease were identified as the cause of inhibitor resistance.
  • Resistance was confirmed through sequence analysis, transfection of mutated replicons, in vitro enzyme assays, and molecular modeling.
  • This study provides a robust in vitro system for studying HCV protease inhibitor resistance.

Outlook:

  • The developed replicon system facilitates the characterization of resistant HCV variants.
  • This aids in the rational design and optimization of novel HCV protease inhibitors for clinical use.
  • Further research can explore broader applications of this system for other antiviral targets.